Search

Your search keyword '"Paz Coll, Antonio"' showing total 8 results
Start Over Author "Paz Coll, Antonio" Language english
8 results on '"Paz Coll, Antonio"'

1. Safety and efficacy of asciminib treatment in chronic myeloid leukemia patients in real-life clinical practice

Author

Garcia-Gutiérrez, Valentín, Luna, Alejandro, Alonso-Dominguez, Juan M., Estrada, Natalia, Boque, Concepcion, Xicoy, Blanca, Giraldo, Pilar, Angona, Anna, Alvarez-Larrán, Alberto, Sanchez-Guijo, Fermin, Ramírez, María José, Mora, Elvira, Vélez, Patricia, Rosell, Ana, Colorado Araujo, Mercedes, Cuevas, Beatriz, Sagüés, Miguel, Cortes, Montserrat, Encinas, Manuel Perez, Casado Montero, Luis Felipe, Moreno Vega, Melania, Serrano, Luis, Gomez, Valle, Garcia-Hernandez, Carmen, Lakhwani, Sunil, Paz Coll, Antonio, de Paz, Raquel, Suarez-Varela, Sara, Fernandez-Ruiz, Andrés, Perez Lopez, Raul, Ortiz-Fernández, Almudena, Jiménez-Velasco, Antonio, Steegmann-Olmedillas, Juan Luis, and Hernández-Boluda, Juan Carlos

Published
2021
Full Text
View/download PDF

2. Toxicity of Asciminib in Real Clinical Practice; Analysis of Side Effects and Cross-Intolerance with Tyrosine Kinase Inhibitors

Author

Pérez-Lamas, Lucía, Luna, Alejandro, Boque, Concepcion, Senin, María Alicia, Xicoy, Blanca, Giraldo, Pilar, Perez Lopez, Raul, Ruiz Nuño, Concepción, De las Heras, Natalia, Mora Casterá, Elvira, Garcia-Hernandez, Carmen, Segura Diaz, Adrian, Steegmann, Juan Luis, Velez Tenza, Patricia, Sanchez-Guijo, Fermin, Garcia-Noblejas Moya, Ana Maria, Juan Vera Goñi, Juan Antonio, Moreno Vega, Melania, Alvarez-Larran, Alberto, Cortes, Montse, Perez Encinas, Manuel, Serrano, Luis, Angona, Anna, Rosell, Ana, Lakhwani, Sunil, Colorado, Mercedes, Ramila, Elena, Cervero, Carlos, Cuevas, Beatriz, Villalon Blanco, Lucia, Hernandez Boluda, Juan Carlos, Paz Coll, Antonio, Gómez García de Soria, Valle, Fernández, Maria Jose, Casado, Luis Felipe, Alonso-Dominguez, Juan Manuel, Anguita Arance, Maria Magdalena, Carrascosa Mastell, Patricia, Salamanca Cuenca, Araceli, Jiménez-Velasco, Antonio, Ramírez, María José, López Esteban, Miguel, Sierra Pacho, Magdalena, Santaliestra, Marta, Alda Alvarez, Olga, de Paz, Raquel, and García Gutiérrez, Valentín

Published
2022
Full Text
View/download PDF

3. Outcomes of Chronic Myeloid Leukemia Patients after Therapeutic Failure to Asciminib, a Multicenter Observational Study

Author

Pérez-Lamas, Lucía, Segura Diaz, Adrian, Mora, Elvira, Hidalgo Soto, Marta, Paz Coll, Antonio, De Las Heras, Natalia, Cortes, Montse, Velez Tenza, Patricia, Sierra Pacho, Magdalena, Senin, María Alicia, Angona, Anna, Cervero, Carlos, De Paz Arias, Raquel, Salamanca Cuenca, Araceli, Santaliestra, Marta, López Marin, Javier, Casado Montero, Luis Felipe, and García Gutiérrez, Valentín

Published
2023
Full Text
View/download PDF

4. Asciminib in Real-Life Clinical Practice, Safety and Efficacy Profile in Chronic Myeloid Leukemia Pretreated Patients

Author

Pérez-Lamas, Lucía, Luna, Alejandro, Boque, Concepcion, Giraldo, Pilar, Xicoy, Blanca, Casado, Luis Felipe, Sanchez-Guijo, Fermin, Ruiz Nuño, Concepción, Moreno Vega, Melania, Alvarez-Larran, Alberto, Salamanca Cuenca, Araceli, García-Noblejas, Ana, Vall-Llovera, Ferran, Perez Encinas, Manuel, Villalon, Lucia, De las Heras, Natalia, Lakhwani, Sunil, Ramila, Elena, Cuevas, Beatriz, Perez Lopez, Raul, Jiménez-Velasco, Antonio, Rosell, Ana, Escola, Angeles, Fernández, Maria Jose, Garcia-Hernandez, Carmen, Cervero, Carlos, Mora Casterá, Elvira, Sagüés, Miguel, Suarez-Varela, Sara, Vélez, Patricia, Carrascosa Mastell, Patricia, Fé Bitaube, Rocio, Serrano, Luis, Cortes, Montse, Juan Vera Goñi, Juan Antonio, Steegmann, Juan Luis, Hernandez Boluda, Juan Carlos, Gomez, Valle, Alonso-Dominguez, Juan Manuel, Araujo, Mercedes Colorado, Paz Coll, Antonio, and Garcia Gutierrez, Valentín

Published
2021
Full Text
View/download PDF

5. Safety and Efficacy Profile of Asciminib As Treatment in Chronic Myeloid Leukemia Patients after Several Tyrosine-Kinase Inhibitors Failure

Author

Luna, Alejandro, Estrada, Natalia, Boque, Concepcion, Xicoy, Blanca, Giraldo, Pilar, Angona, Anna, Alvarez-Larrán, Alberto, Sanchez-Guijo, Fermin, Ramírez, María José, Alonso-Domínguez, Juan M., Mora, Elvira, Vélez, Patricia, Rosell, Ana, Araujo, Mercedes Colorado, Cuevas, Beatriz, Sagüés, Miguel, Cortes, Montserrat, Perez Encinas, Manuel, Casado Montero, Luis Felipe, Moreno Vega, Melania, Serrano, Luis, Gomez, Valle, Garcia-Hernandez, Carmen, Lakhwani Lakhwani, Sunil, Paz Coll, Antonio, de Paz, Raquel, Suarez-Varela, Sara, Fernandez-Ruiz, Andrés, Perez Lopez, Raul, Ortiz-Fernández, Almudena, Jiménez-Velasco, Antonio, and Garcia-Gutiérrez, Valentín

Published
2020
Full Text
View/download PDF

7. Toxicity of Asciminib in Real Clinical Practice: Analysis of Side Effects and Cross-Toxicity with Tyrosine Kinase Inhibitors.

Author

Pérez-Lamas L, Luna A, Boque C, Xicoy B, Giraldo P, Pérez López R, Ruiz Nuño C, De Las Heras N, Mora Casterá E, López Marín J, Segura Díaz A, Gómez V, Vélez Tenza P, Sierra Pacho M, Vera Goñi JA, Moreno Vega M, Alvarez-Larrán A, Cortés M, Pérez Encinas M, Carrascosa Mastell P, Angona A, Rosell A, Lakhwani S, Colorado M, Ramila E, Cervero C, Cuevas B, Villalón Blanco L, de Paz R, Paz Coll A, Fernández MJ, Felipe Casado L, Alonso-Domínguez JM, Anguita Arance MM, Salamanca Cuenca A, Jiménez-Velasco A, Prendes SO, Santaliestra M, Lis Chulvi MJ, Hernández-Boluda JC, and García-Gutiérrez V

Abstract

(1) Background: Despite the prognostic improvements achieved with tyrosine kinase inhibitors (TKIs) in chronic myeloid leukemia (CML), a minority of patients still fail TKIs. The recent introduction of asciminib may be a promising option in intolerant patients, as it is a first-in-class inhibitor with a more selective mechanism of action different from the ATP-competitive inhibition that occurs with TKIs. Therefore, our goal was to analyze toxicities shown with asciminib as well as to study cross-toxicity with previous TKIs. (2) Methods: An observational, multicenter, retrospective study was performed with data from 77 patients with CML with therapeutic failure to second-generation TKIs who received asciminib through a managed-access program (MAP) (3) Results: With a median follow-up of 13.7 months, 22 patients (28.5%) discontinued treatment: 32% (7/22) due to intolerance and 45% (10/22) due to resistance. Fifty-five percent of the patients reported adverse effects (AEs) with asciminib and eighteen percent grade 3-4. Most frequent AEs were: fatigue (18%), thrombocytopenia (17%), anemia (12%), and arthralgias (12%). None of the patients experienced cardiovascular events or occlusive arterial disease. Further, 26%, 25%, and 9% of patients required dose adjustment, temporary suspension, or definitive discontinuation of treatment, respectively. Toxicities under asciminib seemed lower than with prior TKIs for anemia, cardiovascular events, pleural/pericardial effusion, diarrhea, and edema. Cross-toxicity risk was statistically significant for thrombocytopenia, anemia, neutropenia, fatigue, vomiting, and pancreatitis. (4) Conclusion: Asciminib is a molecule with a good safety profile and with a low rate of AEs. However, despite its new mechanism of action, asciminib presents a risk of cross-toxicity with classical TKIs for some AEs.

Published
2023
Full Text
View/download PDF

8. Do chronic myeloid leukemia patients with late "warning" responses benefit from "watch and wait" or switching therapy to a second generation tyrosine kinase inhibitor?

Author

García-Gutiérrez V, Puerta JM, Maestro B, Casado Montero LF, Muriel A, Molina Hurtado JR, Perez-Encinas M, Moreno Romero MV, Suñol PB, Sola Garcia R, De Paz R, Ramirez Sanchez MJ, Osorio S, Mata Vazquez MI, Martinez López J, Sastre JL, Portero Mde L, Bautista G, Duran Nieto MS, Giraldo P, Jimenez Jambrina M, Burgaleta C, Ruiz Aredondo J, Peñarrubia MJ, Requena MJ, Fernández Valle Mdel C, Calle C, Paz Coll A, Hernández-Rivas JÁ, Franco Osorio R, Cano P, Tallón Pérez D, Fernández de la Mata M, Garrido PL, and Steegmann JL

Subjects
Benzamides pharmacology, Clinical Trials, Phase III as Topic, Disease-Free Survival, Drug Resistance, Neoplasm, Fusion Proteins, bcr-abl antagonists & inhibitors, Humans, Imatinib Mesylate, Leukemia, Myelogenous, Chronic, BCR-ABL Positive blood, Leukemia, Myelogenous, Chronic, BCR-ABL Positive mortality, Multicenter Studies as Topic, Piperazines pharmacology, Protein Kinase Inhibitors administration & dosage, Pyrimidines pharmacology, Randomized Controlled Trials as Topic, Survival Analysis, Treatment Outcome, Benzamides therapeutic use, Biomarkers, Tumor blood, Drug Substitution, Fusion Proteins, bcr-abl blood, Leukemia, Myelogenous, Chronic, BCR-ABL Positive drug therapy, Piperazines therapeutic use, Protein Kinase Inhibitors therapeutic use, Pyrimidines therapeutic use, Watchful Waiting
Abstract

In the latest recommendations for the management of chronic-phase chronic myeloid leukemia suboptimal responses have been reclassified as "warning responses." In contrast to previous recommendations current guidance advises close monitoring without changing therapy. We have identified 198 patients treated with first-line imatinib, with a warning response after 12 months of treatment (patients with a complete cytogenetic response but no major molecular response [MMR]). One hundred and forty-six patients remained on imatinib, while 52 patients changed treatment to a second generation tyrosine kinase inhibitor (2GTKI). Changing therapy did not correlate with an increase in overall survival or progression-free survival. Nevertheless, a significant improvement was observed in the probability of a MMR: 24% vs. 42% by 12 months and 43% vs. 64% by 24 months (P = 0.002); as well as the probability of achieving a deep molecular responses (MR(4.5) ): 1% vs. 17% and 7% vs. 23% by 12 and 24 months, respectively (P = <0.001) .The treatment change to 2GTKI remained safe; however, we have observed a 19% of treatment discontinuation due to side effects. We have observed an improvement of molecular responses after changing treatment to 2GTKI in patients with late suboptimal response treated with imatinib first line. However, these benefits were not correlated with an improvement of progression free survival or overall survival., (© 2014 Wiley Periodicals, Inc.)

Published
2014
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results